EBOSF (Ebos Group) Growth Rank: 10 (As of Jul. 30, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBOSF Ebos Group Ltd EBOSF
85 GF Score
Price $23.75
GF Value $43.41
! 4 Warning Signs
View Full Analysis

What is Ebos Group Growth Rank?

Ebos Group EBOSF +15.85% 85 Growth Rank is 10 as of Jul. 30, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates EBOSF with a GF Score™ of 85/100 and a GF Value™ of $43.41. The stock has 4 warning signs investors should review.

Ebos Group has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

EBOSF vs MCK, COR, CAH: Growth Rank Comparison

For the Medical Distribution subindustry, Ebos Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group Growth Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where Ebos Group's Growth Rank falls into.


EBOSF
85GF Score
Ebos Group Ltd EBOSF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Ebos Group (EBOSF) has a Growth Rank of 10 as of Jul. 30, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ebos Group and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Ebos Group's Growth Rank has ranged from 5.00 to 10.00.
Is Ebos Group's Growth Rank too high?
Ebos Group's current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Growth Rank compare to MCK and COR?
Ebos Group's Growth Rank of 10 can be compared against companies in the Medical Distribution industry. Historically, Ebos Group's own Growth Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Distribution company?
A good Growth Rank depends on the Medical Distribution industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Ebos Group and its competitors. Ebos Group's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current Growth Rank of 10. The stock's GF Value™ is $43.41, compared to a current price of $23.75 — trading 45.3% below its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Ebos Group (EBOSF), the current Growth Rank is 10 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (EBOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of $23.75 is trading 45.3% below its estimated GF Value™ of $43.41.

Key valuation signals for EBOSF:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: $43.41 vs. price of $23.75 (45.3% below fair value)
  • GF Score™: 85/100 with 4 warning signs

No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score

Get the complete analysis for EBOSF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.75
Price
$43.41
GF Value